Essential Amino Acid Blends

Essential Amino Acid Blends

Compiled by South Beach Longevity · 20 August 2026 Copyright 2026 Series SBL-41 / SP-ESSENTIAL-AMINO-ACID-BLENDS · Register A scientific article Sources peer-reviewed human trials, metabolic studies, requirement methods, and labelled animal or in-vitro work · verified NCBI records Constraint This document describes published research. It is not medical advice. No human use, dose, route or schedule is recommended anywhere in this document.

How to read this document Every finding is labelled, in the sentence that reports it, by the kind of study that produced it. A primed myofibrillar fractional synthesis rate is not hypertrophy. A whey comparison in young men is not a sarcopenia trial. A commercial ratio is not the mixture used in the paper it cites. Amounts appear only as reported experimental parameters, always with the population attached. Nothing here is a recommendation.

The sibling Amino-Acid Nutrition article is the twenty-monomer system: chemistry, first-pass metabolism, scoring, life stage, and isolated-amino-acid controversies. This title is the product-class problem. The two documents share physiology. They do not share a question.

Findings are graded in place as established, strongly supported, supported, emerging, plausible, or speculative, and where a claim fails on its own evidence, as refuted. Two further labels mark careful absences rather than verdicts: not established, where the evidence is too thin to place a claim on the ladder at all — untested or insufficient, an absence of proof rather than disproof; and not supported, where the weight of evidence leans against a claim but stops short of a formal refutation.

01 The nine indispensable amino acids

A healthy adult cannot make, at a sufficient rate, nine of the twenty proteinogenic amino acids: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. Nutrition science calls them indispensable, or essential. The remaining eleven can be made from other carbon skeletons if nitrogen is available; several of those become conditionally indispensable in growth, pregnancy, or catabolic illness. Arginine is the usual example. It is not one of the nine, and adding it to an “EAA blend” does not make the blend a complete protein food (Young and Borgonha, 2000; WHO/FAO/UNU, 2007).

The nine are not interchangeable. Lysine is limiting in many cereals. The sulfur amino acids (methionine plus cysteine) are limiting in many legumes. Tryptophan is present in small mass but is the starting material for serotonin and NAD pathways. Leucine is the most discussed signal for mTORC1 in skeletal muscle. Isoleucine and valine share the branched-chain aminotransferase and the branched-chain ketoacid dehydrogenase complex with leucine; they are not leucine (Harper, Miller, and Block, 1984). Histidine was late to the adult indispensable list because short nitrogen-balance studies missed the slow drain of the hemoglobin and carnosine pools (Kopple and Swendseid, 1975; WHO/FAO/UNU, 2007).

An essential amino-acid blend, in this article, is a mixture of free (or, less often, peptide-bound) indispensable amino acids sold or studied as a unit, without an intact food-protein matrix. The definition excludes a single amino acid, a BCAA-only product, a collagen hydrolysate, and a protein powder. Those comparators appear because they are what the blends are sold against.

02 Indispensable requirements

Human indispensable-amino-acid requirements were first estimated by nitrogen balance and later re-estimated by indicator amino-acid oxidation (IAAO) and related carbon-oxidation methods. The two families do not always agree. Nitrogen balance underestimates some requirements because unmeasured losses and adaptive reductions in oxidation flatten the apparent need (Young and Borgonha, 2000; Millward, 1998). IAAO often returns higher point estimates. Elango, Ball, and Pencharz have argued that the indicator method is the better adult tool (Elango, Ball, and Pencharz, 2008). Millward has argued that method is not destiny and that habitual protein intakes already cover most IAA needs in mixed diets (Millward, 2012). The disagreement is a methods fact. It is not a licence to treat a supplement label as a requirement table.

The Institute of Medicine 2005 adult estimates, in mg·kg⁻¹·d⁻¹, were histidine 14, isoleucine 19, leucine 42, lysine 38, methionine plus cysteine 19, phenylalanine plus tyrosine 33, threonine 20, tryptophan 5, and valine 24 (Institute of Medicine, 2005). The WHO/FAO/UNU 2007 scoring pattern, expressed as mg per gram of protein, put leucine at 59, lysine at 45, and tryptophan at 6 (WHO/FAO/UNU, 2007). Those numbers describe the amino-acid pattern of a protein that would meet adult IAA needs at the protein requirement. They are not a hypertrophy prescription, not an older-adult meal target, and not a bottle formula.

Protein quality scores — PDCAAS and DIAAS — rank foods by digestible indispensable amino acids (Schaafsma, 2000; FAO, 2013). They do not rank free-amino-acid mixtures. A free EAA blend can be written to any pattern the formulator chooses. That is a manufacturing fact. It is not evidence that the chosen pattern is physiologically privileged.

03 Protein synthesis, breakdown, and nitrogen

Skeletal-muscle protein is not a store in the glycogen sense. It is a large, slowly turning pool whose net change is the difference between synthesis and breakdown. A mixed meal, a free-amino-acid drink, insulin, and resistance exercise each move the two rates. They do not move them by the same amount or for the same duration (Biolo, Tipton, Klein, and Wolfe, 1997; Rennie et al., 2002).

Bohé, Low, Wolfe, and Rennie showed, in human infusion studies, that extracellular essential-amino-acid availability drives the rise in muscle protein synthesis, with a latency and a duration that are hours, not days (Bohé et al., 2001, 2003). Atherton and colleagues later described a “muscle-full” set-point: after a protein or amino-acid bolus, myofibrillar synthesis rises and then returns toward baseline even while amino acids remain elevated (Atherton et al., 2010). Greenhaff and colleagues showed that amino-acid and insulin effects on synthesis and breakdown can dissociate (Greenhaff et al., 2008). Those tracer facts are established as acute physiology. They are the mechanism the blend market treats as a result.

Nitrogen metabolism sits underneath. Amino-acid oxidation, urea synthesis, and the disposal of leftover carbon skeletons rise when intake exceeds the capacity to incorporate nitrogen into protein. A free-amino-acid drink that spikes plasma concentrations also spikes oxidation (Groen et al., 2015; Wolfe, 2017). Rapid appearance is not free. The unused monomers are burned.

04 Digestion versus free-amino-acid absorption

Intact protein must be emptied from the stomach, hydrolysed by pepsin, trypsin, and the brush-border peptidases, and absorbed as free amino acids and small peptides on PEPT1 and the amino-acid transporters. A large and amino-acid-specific fraction is then extracted by the splanchnic bed — gut and liver — before any peripheral tissue sees it (Matthews, Mariss, and Bier, 1981; Stoll and Burrin, 2006). First-pass extraction is not a tax on “quality.” It is how the portal-drained viscera are fed.

Free EAAs skip the hydrolysis step. Plasma appearance is faster and the peak is higher for a given ingested mass. That is the pharmacokinetic claim the category lives on, and it is strongly supported as kinetics (Boirie et al., 1997; Dangin et al., 2001; Volpi et al., 2003). Whether the faster peak is an advantage depends on the question. For a four-hour myofibrillar FSR, a complete EAA mixture can match or exceed a larger intact-protein meal because the muscle sees a full indispensable set quickly (Volpi et al., 2003; Paddon-Jones et al., 2005). For a twelve-hour or twenty-four-hour balance, the slower, longer aminoacidemia of casein and mixed meals remains anabolic after the free-amino-acid peak has fallen (Boirie et al., 1997; Dangin et al., 2001; Trommelen et al., 2018). Speed and duration are different properties. The market quotes the first and forgets the second.

Free amino acids also taste bitter, osmolar loads are higher, and gastrointestinal discomfort is common in the trial record when doses rise. Those are practical facts, not a moral argument against the form.

05 Leucine threshold concepts and amino-acid balance

Leucine activates mTORC1 through Sestrin2 and related sensors in cells (Wolfson et al., 2016). In human muscle, a leucine-rich drink phosphorylates mTORC1 targets and can raise myofibrillar FSR when the other indispensable amino acids are present (Atherton et al., 2010; Churchward-Venne et al., 2012). The applied slogan is a leucine threshold: something near 2–3 g of leucine in a meal for young adults, higher in older adults, often quoted as 2.5–2.8 g in the PROT-AGE consensus (Bauer et al., 2013).

The slogan is a useful acute description. It is not a daily law. Churchward-Venne and colleagues showed, in young men, that adding leucine to a small whey dose could raise acute MPS toward the level of a larger whey dose (Churchward-Venne et al., 2012, 2014). Katsanos, Kobayashi, Sheffield-Moore, Aarsland, and Wolfe showed, in older adults, that a 6.7 g EAA drink with 41% leucine raised MPS where the same nitrogen with 26% leucine did not (Katsanos et al., 2006). Those are strongly supported acute findings. They do not prove that every breakfast must clear a leucine bar, or that extra leucine on top of an already adequate protein day adds muscle.

Balance is the veto. Muscle protein synthesis requires all indispensable amino acids as substrate. Leucine is a signal and a substrate. If the other eight are missing, the signal has nothing to build with. Wolfe’s 2017 review of isolated BCAAs is the chemical statement of that veto (Wolfe, 2017). The same veto applies to leucine-only products and to any “EAA” blend that is, on assay, a BCAA drink with a dusting of the rest.

06 Intact mixed-meal protein

A mixed meal delivers indispensable and dispensable amino acids, energy, micronutrients, and a food matrix that slows gastric emptying. Paddon-Jones and colleagues compared, in healthy adults, a 90 g serving of lean beef with a smaller free-EAA drink designed to match the beef’s EAA content; the smaller EAA drink produced a comparable acute MPS response (Paddon-Jones et al., 2005). That result is the category’s favorite slide. It is also a four-hour measurement after a single feeding. It does not show that the rest of the beef — energy, non-essential nitrogen, iron, and satiety — is nutritionally idle.

Mamerow and colleagues reported, in a human crossover, that even distribution of protein across meals supported a higher 24-hour mixed-muscle protein synthesis than a skewed pattern with the same daily protein (Mamerow et al., 2014). The finding is about meal pattern, not about bottles. An EAA drink can be used as one of those meals in a protocol. That is not evidence that the drink replaces the day’s food.

07 Whey

Whey is the fast dairy protein: rapidly digested, leucine-rich, and the most repeated acute-MPS comparator in the exercise literature. Tang, Moore, Wilkinson, Tarnopolsky, and Phillips showed, in young men after resistance exercise, that whey hydrolysate raised mixed-muscle protein synthesis more than soy or casein at matched protein (Tang et al., 2009). Pennings and colleagues found a similar whey advantage in older men (Pennings et al., 2011). Witard and colleagues mapped a whey-protein dose–response for myofibrillar synthesis after exercise in young men (Witard et al., 2014). Moore and colleagues had already shown a hyperbolic ingested-protein dose–response in young men after resistance exercise (Moore et al., 2009).

EAA blends are often marketed as “whey without the calories.” The honest comparison is not calorie-free magic. It is a smaller EAA mass versus a larger whey mass, with the whey still winning or tying when EAA content is matched, and the whey still providing non-essential amino acids and a food matrix (Katsanos et al., 2008; Paddon-Jones et al., 2005; Kim et al., 2016). Kim, Schutzler, Schrader, Spencer, Azhar, Ferrando, and Wolfe reported that older adults needed a larger protein meal than young adults to maximize MPS, and that EAA content, not merely total protein, tracked the response (Kim et al., 2015, 2016). That is an argument for protein quality and meal size in older adults. It is not an argument that a 5 g proprietary blend replaces a whey feeding.

08 Casein

Casein is the slow dairy protein. Boirie, Dangin, Gachon, Vasson, Maubois, and Beaufrère labelled whey “fast” and casein “slow” in a human leucine-tracer study: whey produced a taller, shorter aminoacidemia and more oxidation; casein produced a lower, longer aminoacidemia and a better net leucine balance over the feeding window (Boirie et al., 1997; Dangin et al., 2001). Trommelen, Holwerda, Kouw, and van Loon later used pre-sleep casein to extend overnight MPS in human trials (Trommelen et al., 2017, 2018; Holwerda et al., 2016).

If the commercial claim is that faster is better, casein is the inconvenient control. If the claim is that a complete amino-acid pattern at the muscle is better, casein and whey are both complete dairy proteins with different time courses. An EAA blend can be formulated to look like whey. It cannot, without a delivery trick, look like casein. Micellar or sustained-release amino-acid products exist as marketing language. Human head-to-heads against micellar casein on hypertrophy are not a literature.

09 Plant protein

Plant proteins are not one object. Soy isolate is relatively complete and has a human acute-MPS literature; it usually sits below whey at matched grams (Tang et al., 2009; Yang et al., 2012). Wheat, rice, and pea are more often limited by lysine or methionine. Gorissen, Crombag, Senden, Waterval, Bierau, Verdijk, and van Loon tabulated amino-acid composition and digestibility across commercial plant and animal isolates (Gorissen et al., 2018). Pinckaers, Trommelen, Snijders, and van Loon have reviewed why plant proteins often produce a smaller acute MPS response per gram and what blending or fortification does to that gap (Pinckaers et al., 2021). van Vliet, Burd, and van Loon framed the plant-versus-animal question as composition plus digestion, not as a slogan (van Vliet, Burd, and van Loon, 2015).

An EAA blend can repair a plant meal’s limiting amino acids. That is the oldest use of crystalline amino acids in nutrition: lysine in cereal fortification, not a gym powder. The public-health evidence for lysine fortification of wheat is a different file from a recreational EAA bottle taken on top of an already mixed diet (Young and Pellett, 1994). This article does not spend the fortification evidence as a hypertrophy claim.

10 Branched-chain amino acids

Isoleucine, leucine, and valine are three of the nine. A BCAA product is not an EAA blend. Wolfe’s 2017 review is the load-bearing paper: isolated BCAAs cannot support a rise in muscle protein synthesis because the other indispensable amino acids are not supplied; any increase in synthesis would have to come from endogenous breakdown (Wolfe, 2017). Jackman, Witard, Philp, Wallis, Baar, and Tipton showed, in resistance-trained men, that BCAA ingestion raised myofibrillar FSR above placebo but to a lesser extent than expected from intact protein (Jackman et al., 2017). Fuchs, Hermans, Smeets, Senden, van Kranenburg, van Loon, and colleagues have continued to treat BCAAs as an incomplete stimulus (Fuchs et al., 2019).

Plotkin and colleagues’ 2021 review of isolated BCAAs for muscle and performance is the applied summary: the acute signal is small; the chronic hypertrophy evidence is weak once protein is controlled (Plotkin et al., 2021). Fedewa’s meta-analyses of BCAA and delayed-onset muscle soreness report small symptom effects in heterogeneous protocols (Fedewa, Spencer, Williams, Crews, and Hanson, 2019). Symptom relief is not hypertrophy. Grade: not supported as a protein replacement; emerging as an acute signalling or soreness adjunct.

11 Leucine alone

Leucine is the most bioactive branched-chain amino acid for mTORC1. Isolated leucine raises signalling and can raise MPS when background protein is present and suboptimal (Churchward-Venne et al., 2012). Isolated leucine as a chronic supplement in protein-adequate older men has a thinner and more disappointing file. Verhoeven, Vanschoonbeek, Verdijk, Koopman, Wodzig, Dendale, and van Loon reported no increase in muscle mass or strength after three months of leucine in healthy older men (Verhoeven et al., 2009). Leenders, Verdijk, van der Hoeven, van Kranenburg, Hartgens, Wodzig, Saris, and van Loon found the same null in older men with type 2 diabetes over six months (Leenders et al., 2011). Those are human randomised trials, not mechanism cartoons.

The contrast is the whole article in miniature. Acute leucine signalling is established. Chronic leucine as a muscle drug in already fed older adults is not supported by the better RCTs. Adding leucine to an EAA mixture is a different experiment from swallowing leucine alone.

12 Acute muscle protein synthesis

The cleanest human demonstration that EAAs carry the anabolic effect of a mixed-amino-acid drink is Volpi, Kobayashi, Sheffield-Moore, Mittendorfer, and Wolfe (2003). In healthy older adults, 18 g of essential amino acids stimulated muscle protein anabolism to a similar extent as 40 g of mixed amino acids containing the same 18 g of EAAs plus dispensable amino acids. The dispensable amino acids were not required for the acute stimulation. That is established as an acute, tracer-measured fact in that population and protocol.

Tipton, Ferrando, Phillips, Doyle, and Wolfe had already shown that a small EAA plus carbohydrate drink around resistance exercise raised muscle protein synthesis in young adults (Tipton et al., 1999, 2001). Børsheim, Tipton, Wolf, and Wolfe reported a dose-related EAA effect on net muscle protein balance after exercise (Børsheim et al., 2002). Drummond, Dreyer, Fry, Glynn, and Rasmussen mapped the mTORC1 phosphorylation that accompanies those drinks in young and older adults (Drummond et al., 2008; Dickinson et al., 2011). Fry, Drummond, Glynn, Dickinson, Gundermann, Walker, and Rasmussen showed that older muscle can be resistant at the signalling step after exercise even when amino acids are supplied (Fry et al., 2011). Cuthbertson, Smith, Babraj, Leese, Waddell, Atherton, Wackerhage, Taylor, and Rennie had named that anabolic resistance in a human dose–response of EAAs against MPS and signalling (Cuthbertson et al., 2005).

The oversell is the leap from those hours to a training year. Mitchell, Churchward-Venne, Cameron-Smith, and Phillips reviewed the poor ranking of hypertrophy by acute post-exercise MPS (Mitchell et al., 2015). Damas, Phillips, Libardi, Vechin, Lixandrão, Jannig, and colleagues showed that early elevations in MPS after unaccustomed exercise include damage-repair synthesis that does not predict growth (Damas et al., 2016). Wilkinson, Franchi, Brook, Narici, Williams, Mitchell, and colleagues used deuterated water to integrate synthesis over days and weeks — a different measurement from a primed four-hour infusion (Wilkinson et al., 2014; Brook et al., 2015). Acute FSR remains a valid mechanistic endpoint. It is not a hypertrophy endpoint.

13 Hypertrophy

Hypertrophy is an increase in fibre cross-sectional area or in imaging-measured muscle size over weeks to months of loading, with protein intake as a modifier. Morton, Murphy, McKellar, Schoenfeld, Henselmans, Helms, Aragon, Devries, Banfield, Krieger, and Phillips’s 2018 meta-analysis of protein supplementation during resistance training found a small lean-mass increment that plateaued near the mid-1 g·kg⁻¹ range in already trained adults (Morton et al., 2018). Nunes, Colenso-Semple, McKellar, Gasperotti, Kumbhare, and colleagues later updated the protein-and-lean-mass file (Nunes et al., 2022). Those metas are protein metas. They are not EAA-blend metas.

Chronic EAA-blend hypertrophy trials are fewer, smaller, and more often conducted in older or clinical samples than in young gym-goers. Dillon, Sheffield-Moore, Paddon-Jones, Gilkison, Sanford, Casperson, Jiang, Chinkes, and Urban reported that three months of EAA supplementation in older women increased lean mass modestly without a change in strength (Dillon et al., 2009). Ispoglou, White, King, and colleagues reported mixed body-composition and function findings with EAA or leucine-enriched mixtures in older adults (Ispoglou et al., 2011, 2016). Markofski, Jennings, Dolan, Davies, LaVoy, and colleagues reported that chronic EAA supplementation in older adults could raise basal MPS and mTOR signalling without a large change in lean mass (Markofski et al., 2018). The pattern is consistent: acute FSR moves; DXA and dynamometry move little or not at all when habitual protein is already near requirement.

In young, protein-sufficient trainees, the default expectation from the protein metas is that an EAA blend added on top of an already adequate diet will not be a hypertrophy intervention. That is an inference from the protein file plus the leucine RCTs, not a large dedicated EAA-versus-whey hypertrophy literature. The gap should be named, not filled with mechanism.

14 Older adults and sarcopenia

Anabolic resistance is strongly supported as an acute-tracer phenomenon: older muscle needs a larger EAA or protein stimulus to reach a young-adult MPS response (Cuthbertson et al., 2005; Moore et al., 2015; Wall et al., 2015). PROT-AGE recommended higher daily protein and a per-meal protein and leucine target for older adults (Bauer et al., 2013). The ESPEN expert group made a similar protein-intake case (Deutz et al., 2014). EWGSOP2 defined sarcopenia as low muscle strength, with low mass as a confirmer and low performance as a severity marker (Cruz-Jentoft et al., 2019). Those are consensus documents. They recommend food protein first.

Human EAA trials in older adults split by endpoint.

Acute MPS. Volpi 2003, Katsanos 2006, Paddon-Jones 2005, Bukhari, Phillips, Wilkinson, Limb, Rankin, Mitchell, and colleagues (2015), and Kim 2015–2016 are the core. Complete EAA drinks raise MPS; leucine proportion matters more in older adults; a small EAA dose can match a larger mixed-protein feeding on a four-hour FSR.

Lean mass and function. Dillon 2009 (modest lean mass, no strength). Solerte, Gazzaruso, Schifino, Fioravanti, D’Addato, Ventura, and colleagues reported improved insulin sensitivity and lean mass with oral amino-acid mixtures in older adults with sarcopenia — open or lightly controlled designs (Solerte et al., 2008). Rondanelli, Opizzi, Antoniello, Boschi, Iadarola, and colleagues reported function and body-composition gains with EAA mixtures in institutionalised or sarcopenic older adults (Rondanelli et al., 2011, 2016). Negro, Perna, Spadaccini, Castelli, Rondanelli, and colleagues have continued that Italian clinical-nutrition line (Negro et al., 2019). These trials are human, often small, sometimes unblinded, and not consistently protein-matched against an isonitrogenous food control. Grade: emerging to supported for lean mass or function in protein-inadequate or clinical older samples; not supported as a substitute for protein-plus-resistance-training in community-dwelling older adults who already eat enough protein.

The leucine-only RCTs in healthy older men (Verhoeven 2009; Leenders 2011) are the warning against treating anabolic resistance as a licence for a leucine drug.

15 Energy deficit

Energy deficit raises the cost of preserving lean mass. Areta, Burke, Camera, West, Crawshay, Moore, Stellingwerff, Phillips, Hawley, and Coffey showed that a large energy deficit reduced myofibrillar synthesis in trained adults and that protein feeding still stimulated MPS, though from a lower baseline (Areta et al., 2014). Hector, Marcotte, Churchward-Venne, Murphy, Breen, von Allmen, and Phillips compared whey and soy during a short energy deficit in overweight adults; higher-quality protein better supported MPS (Hector et al., 2015). Pasiakos, Cao, Margolis, Sauter, Whiteman, McClung, and colleagues mapped protein and EAA needs in military-style energy deficit (Pasiakos et al., 2013).

Gwin, Church, Hatch-McChesney, Allen, Galvan, Wolfe, Ferrando, Pasiakos, and colleagues have tested free EAA ingestion during energy deficit in humans: EAA drinks can restore a deficit-suppressed MPS response toward the fed, energy-adequate level in short protocols (Gwin et al., 2020, 2021). That is a plausible to strongly supported acute finding in a defined military and laboratory setting. It is not a field demonstration that a small EAA bottle replaces rations, and it is not a hypertrophy trial in a cut. Coker, Miller, Schutzler, Deutz, and Wolfe reported that an EAA plus whey mixture during a weight-loss intervention in older obese adults helped spare lean mass relative to a control formula (Coker et al., 2012, 2015). Those are small clinical feeding studies. They support a quality-and-EAA-content hypothesis during deficit. They do not support a consumer claim that “10 g of EAAs replaces 30 g of protein” as a general rule.

16 Athletes and recovery

For athletes who already eat high-quality protein at intakes in the range reviewed by Jäger, Kerksick, Campbell, Cribb, Wells, Skwiat, and the ISSN protein position stand (Jäger et al., 2017), an EAA blend is a convenience form: lower volume, faster emptying, usable when food is impractical. Tipton, Rasmussen, Miller, Wolf, Owens-Stovall, Petrini, and Wolfe’s timing work around exercise used EAA plus carbohydrate drinks as the experimental feeding, not as a proof that food fails (Tipton et al., 2001). Schoenfeld, Aragon, and Krieger’s protein-timing meta-analysis found little unique effect of a narrow post-exercise window once total daily protein was controlled (Schoenfeld, Aragon, and Krieger, 2013).

Recovery endpoints — soreness, next-day force, repeated-bout performance — have a BCAA and EAA file that is small and inconsistent once carbohydrate and total protein are matched (Jackman et al., 2017; Fedewa et al., 2019; Plotkin et al., 2021). The ISSN stand treats food-first protein as the default and isolates as a tool when food is not practical (Jäger et al., 2017; Kerksick et al., 2018). That is the honest athletic use-case: logistics, not a secret ratio.

17 Clinical catabolic states

Bed rest, immobilisation, and illness accelerate muscle loss. Paddon-Jones, Sheffield-Moore, Urban, Sanford, Aarsland, Wolfe, and Ferrando showed that EAA plus carbohydrate supplementation during 28 days of bed rest in healthy older adults attenuated the loss of lean mass and strength (Paddon-Jones et al., 2004). Ferrando, Paddon-Jones, Hays, Cadenhead, Ronsen, Grady, and Wolfe reported a similar protective EAA effect during bed rest in older adults (Ferrando et al., 2010). English, Mettler, Ellison, Mamerow, Arentson-Lantz, Pattarini, Ploutz-Snyder, Sheffield-Moore, and Paddon-Jones tested leucine-enriched feedings during bed rest in middle-aged adults (English et al., 2016). Those are human bed-rest trials, not ICU nutrition.

In disease, the file fragments. Aquilani, Viglio, Iadarola, Opasich, Testa, Carbonelli, and colleagues reported EAA mixtures in chronic heart failure and related catabolic outpatients, with mixed functional outcomes (Aquilani et al., 2008, 2019). COPD and rehabilitation studies from the same clinical-nutrition tradition exist and are small. Critical-care amino-acid policy is a different literature — ESPEN and ASPEN guidelines on protein in the ICU — and must not be collapsed into a consumer EAA blend (Singer et al., 2019). Glutamine at high dose in the REDOXS trial produced harm in the critically ill (Heyland et al., 2013). That trial is about glutamine, not about a nine-EAA consumer powder, and it is recorded here only as a boundary: clinical amino-acid intervention is not a gym product with a white coat.

18 Formulations in the literature versus on the shelf

Research mixtures used by Wolfe, Volpi, Paddon-Jones, Katsanos, Ferrando, and colleagues are typically 6–15 g of free EAAs with leucine at roughly 25–40% of the EAA mass, the rest distributed to resemble a high-quality protein’s indispensable pattern. Those mixtures are laboratory objects. Commercial products reuse the language and not always the composition.

A formulation comparison has to hold three things apart: (1) the research EAA mixture used in tracer and small RCTs; (2) leucine-enriched protein (whey plus extra leucine, or a protein plus EAA fortification), which is a different product with its own trials (Churchward-Venne et al., 2012, 2014; Bauer et al., 2015 PROVIDE); (3) consumer EAA powders whose labels range from near-research mixtures to BCAA-heavy drinks with a token lysine and tryptophan.

PROVIDE was a leucine-enriched whey medical nutrition drink in sarcopenic older adults; it improved muscle mass and chair-stand time versus an isocaloric control in a randomised trial (Bauer et al., 2015). It is often cited in EAA marketing. It is a protein drink with extra leucine, not a 5 g free-EAA bottle.

19 Proprietary ratio claims

Several commercial lines claim a unique, patented, or “scientifically balanced” ratio. The most aggressive historical claim is the Master Amino Acid Pattern (MAP) associated with Lucà-Moretti: a specific EAA profile said to achieve net nitrogen utilization near 99%, so that 1–2 g of the pattern could replace much larger protein intakes (Lucà-Moretti, 1998; Lucà-Moretti et al., 2003). Those papers sit in a thin, largely in-house literature. They have not been independently replicated with modern tracer methods as a unique physiology that other complete EAA mixtures lack. Nitrogen-balance methods of that era are the same methods section 02 already treats as treacherous. A 99% utilization figure is not a second human metabolism. Grade: not supported as a distinct, independently verified advantage.

Wolfe-associated commercial mixtures (sold under various brand names over the years) are closer to the research compositions used in the Texas and later Arkansas tracer studies. That proximity is a compositional claim. It is not a trial of the branded tub against an isonitrogenous generic EAA mixture on hypertrophy or function. Where the brand cites Volpi 2003 or Katsanos 2006, it is citing the research mixture, not a consumer lot.

BodyHealth Perfect Amino and similar MAP-descended products recycle the utilization claim. Amino Co, Kion Aminos, Momentous Essential Aminos, and other “research-ratio” powders occupy the Wolfe-adjacent shelf. This article does not assay those products and does not recommend them. It records that no proprietary ratio has a published, independent, protein-matched chronic trial showing superiority to a generic complete EAA mixture or to an isonitrogenous high-quality protein. Until that trial exists, ratio branding is marketing layered on a shared physiology.

Conflicts of interest are part of this file. Wolfe and colleagues have disclosed commercial relationships with EAA products in some papers. That does not invalidate the tracer physiology. It does mean that a branded ratio should not be read as an independent confirmation of the same laboratory’s acute findings.

20 Safety, regulatory class, and cost

Free amino acids in the amounts used in the human studies cited here have a short-term safety record dominated by taste, osmolar gastrointestinal symptoms, and, at high isolated doses, historical concerns that do not generalise to mixed EAA drinks (Institute of Medicine, 2005). Very large single-amino-acid loads — grams of free methionine, tryptophan, or histidine — are a different toxicology and are not this product class. People with maple-syrup-urine disease, urea-cycle disorders, or other inborn errors of amino-acid metabolism are outside the healthy-adult literature; this document does not discuss their management.

In the United States these products are dietary supplements under DSHEA, not drugs, not medical foods unless specifically registered as such, and not interchangeable with hospital amino-acid solutions. Contamination and mislabelling are the same industry problem recorded in the ergogenic-aid and sports-nutrition files (Geyer et al., 2004; Maughan et al., 2018). Third-party testing reduces risk. It does not convert a supplement into a trial.

Cost per gram of indispensable amino acids is higher for free EAA powders than for whey, milk, eggs, or mixed meals in ordinary retail markets. The cost can be justified only if the job is one food cannot do: very low volume, very low calories, or a setting where intact protein is not tolerated. If the job is “get enough protein,” food and whey are the cheaper evidence.

21 Formulation comparison

22 EAA versus protein trial matrix

23 Aging and sarcopenia table

24 Acute versus long-term outcomes

25 Cost and evidence

26 the five owner questions

Does rapid absorption confer a meaningful long-term advantage? No demonstration in the human file. Rapid absorption confers a taller, shorter aminoacidemia and a convenient acute MPS stimulus (Boirie et al., 1997; Volpi et al., 2003). Slow proteins remain anabolic longer (Dangin et al., 2001; Trommelen et al., 2018). Chronic trials have not shown that the faster peak produces more muscle or function than an isonitrogenous intact protein. Speed is a pharmacokinetic property. It is not a long-term outcome.

Can small EAA doses replace adequate dietary protein? Not on the evidence in hand. A small complete EAA dose can replace a larger protein feeding as an acute MPS stimulus (Volpi et al., 2003; Paddon-Jones et al., 2005). Replacement of adequate dietary protein would require energy, non-essential nitrogen, micronutrients, adherence over months, and hard endpoints. Those trials do not exist. The chemical possibility of covering IAA need with crystalline amino acids is how parenteral and some enteral formulae are built. It is not a consumer licence to eat 5 g of powder instead of food.

Are proprietary ratios supported? Not as a distinct, independently verified physiology. Research mixtures have a real acute-MPS literature. MAP-style near-complete utilization claims do not. Branded “Wolfe ratios” cite the research mixtures; they have not beaten a generic complete EAA mixture or an isonitrogenous whey on hypertrophy or function in an independent chronic trial. Ratio is a compositional variable. It is not, on present evidence, a brand.

Are acute MPS findings being oversold? Yes, as a category habit. Acute MPS is a valid mechanistic endpoint and is established for complete EAA drinks. Mitchell 2015 and Damas 2016 are the translation papers: FSR ranking is a poor hypertrophy guide, and early synthesis includes repair. Dillon 2009 is the intra-category warning: FSR and lean-mass stories that do not bring strength. Marketing that treats a four-hour infusion as a training result is overselling.

In which populations might EAAs offer practical advantages? Where intact protein is limited by volume, calories, appetite, or protocol: older adults with low protein intake and anorexia; energy deficit when lean-mass spare is the endpoint and food protein is capped; bed rest and immobilisation as tested by Paddon-Jones 2004 and Ferrando 2010; plant-based patterns that need a limiting IAA repaired; peri-exercise logistics when food is impractical. In young, energy-adequate, protein-replete adults under progressive loading, the practical advantage is convenience, not a unique anabolic biology.

Standing constraint This document describes published research. It is not medical advice. No human use, dose, route or schedule is recommended anywhere in this document. Dietary-protein evidence is never treated as isolated-amino-acid evidence. Acute muscle protein synthesis is never treated as hypertrophy.

References

NCBI-verified bibliography is inserted by the build from manifest/06_references.json.

Evidence handling

Study type is named in the reporting sentence. In vitro means a cell or reconstituted system. Animal names the species. Human means people. Acute tracer endpoints, imaging hypertrophy, clinical function, and consensus statements are not collapsed. Conflict is presented as conflict. Commercial ratio claims are graded on independent human outcomes, not on patents.

Findings are graded in place as established, strongly supported, supported, emerging, plausible, or speculative, and where a claim fails on its own evidence, as refuted. Two further labels mark careful absences rather than verdicts: not established, where the evidence is too thin to place a claim on the ladder at all — untested or insufficient, an absence of proof rather than disproof; and not supported, where the weight of evidence leans against a claim but stops short of a formal refutation. No grade is a recommendation.

Limitations

This title is not the Amino-Acid Nutrition system article, not a sports-nutrition fueling guide, and not a clinical nutrition-support protocol. Full-text retrieval was limited to open sources and NCBI records; some classic papers were verified at the MEDLINE record and abstract. Commercial products were not assayed. The figures are original schematics; no commissioned or third-party plate is used. General reference databases were consulted only to locate literature, never as evidence in their own right.